TURBO UNLIMITED LONG- OPTIONSSCHEIN OHNE STOPP-LOSS-LEVEL - BIOMARIN PHARMACEUTICAL Share Price

Certificat

DE000SD4MAC7

Real-time Boerse Frankfurt Warrants 03:10:04 29/05/2024 pm IST
0.4 EUR -11.11% Intraday chart for TURBO UNLIMITED LONG- OPTIONSSCHEIN OHNE STOPP-LOSS-LEVEL - BIOMARIN PHARMACEUTICAL
Current month-58.04%
1 month-60.50%
Date Price Change
29/24/29 0.4 -11.11%
28/24/28 0.47 -16.07%
27/24/27 0.56 -3.45%
24/24/24 0.58 0.00%
23/24/23 0.58 -12.12%

Real-time Boerse Frankfurt Warrants

Last update May 29, 2024 at 03:10 pm IST

More quotes

Static data

Product typeKnock-Out ohne Stop Loss
Buy / SellCALL
Underlying BIOMARIN PHARMACEUTICAL INC.
IssuerLogo Issuer Société Générale Société Générale
WKN SD4MAC
ISINDE000SD4MAC7
Date issued 12/03/2021
Strike 70.37 $
Maturity Unlimited
Parity 10 : 1
Emission price 2.07
Emission volume N/A
Settlement Barausgleich
Currency EUR

Technical Indicators

Highest since issue 5.28
Lowest since issue 0.4
Spread 0.11
Spread %21.15%

Company Profile

BioMarin Pharmaceutical Inc. (BioMarin) is a biotechnology company, which is engaged in developing and commercializing therapies that address the root cause of genetic conditions. BioMarin's commercial products include Vimizim (elosulfase alpha), Naglazyme (galsulfase), Palynziq (pegvaliase-pqpz), Brineura (cerliponase alfa), Aldurazyme (laronidase), Roctavian (valoctocogene roxaparvovec), Kuvan (sapropterin dihydrochloride), and Voxzogo (vosoritide). Vimizim is an enzyme replacement therapy for the treatment of MPS IVA, a lysosomal storage disorder. The Roctavian is an adeno associated virus (AAV5) vector gene therapy designed to restore factor VIII plasma concentrations in patients with severe hemophilia A. Voxzogo is a once daily injection analog of C-type Natriuretic Peptide (CNP) for the treatment of achondroplasia. Brineura is a recombinant human tripeptidyl peptidase 1 (TPP1) for the treatment of patients with CLN2, a form of Batten disease.
Sector
-
More about the company

Ratings for BioMarin Pharmaceutical Inc.

Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings

Consensus: BioMarin Pharmaceutical Inc.

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
29
Last Close Price
74.43 USD
Average target price
109.3 USD
Spread / Average Target
+46.88%
Consensus